Suppr超能文献

头孢他啶、美罗培南和亚胺培南与阿米卡星对多重耐药铜绿假单胞菌的体外相互作用比较

Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.

作者信息

Giamarellos-Bourboulis E J, Grecka P, Giamarellou H

机构信息

1st Department of Propedeutic Medicine, Athens University, Medical School, Greece.

出版信息

Diagn Microbiol Infect Dis. 1997 Oct;29(2):81-6. doi: 10.1016/s0732-8893(97)00123-5.

Abstract

To evaluate the possibility of an enhanced killing effect by ceftazidime, meropenem, or imipenem with amikacin 26 multiresistant Pseudomonas aeruginosa isolates, to nine anti-pseudomonal antimicrobials of diverse chemical classes were studied. A modified time-kill curve procedure was used with a 16 micrograms/ml concentration of each antimicrobial, i.e. within the range of their serum level; a total of 248 killing-curves were performed. Any > or = 2 log10 decrease of viable cell counts by a combination compared to the most active single agent was considered an adequate enhanced killing effect. The latter was found to be mainly expressed at 24 h of growth and involved 30-50% of the tested isolates. The above findings were independent of the MIC level to any individual beta-lactam or to amikacin. It is concluded that there is no difference between the activity of the ceftazidime and amikacin combination and those of meropenem or imipenem with amikacin on multiresistant P. aeruginosa.

摘要

为评估头孢他啶、美罗培南或亚胺培南与阿米卡星联合使用对26株多重耐药铜绿假单胞菌的增强杀菌效果,研究了这三种药物与九种不同化学类别的抗假单胞菌抗菌药物的联合作用。采用改良的时间杀菌曲线法,每种抗菌药物的浓度为16微克/毫升,即在其血清水平范围内;共进行了248次杀菌曲线实验。与活性最强的单一药物相比,联合用药使活菌数减少≥2 log10被认为具有足够的增强杀菌效果。后者主要在生长24小时时表现出来,涉及30%至50%的受试菌株。上述结果与任何一种β-内酰胺类药物或阿米卡星的最低抑菌浓度水平无关。结论是,头孢他啶与阿米卡星联合用药以及美罗培南或亚胺培南与阿米卡星联合用药对多重耐药铜绿假单胞菌的活性没有差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验